by Dan DeMarle | Dec 12, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Other Health Impairment
“Researchers have found evidence that children with high levels of attention-deficit/hyperactivity disorder (ADHD) symptoms show structural brain abnormalities, but treatment with stimulant medications can normalize these differences. This study, published in...
by Dan DeMarle | Dec 12, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Other Health Impairment
“Public perception of mental health has experienced a shift in recent years, thanks in part to public figures, like Olympian gymnast Simone Biles, who stepped away from the 2021 Tokyo Olympics for her mental health. Biles’ public display of self-care certainly...
by Dan DeMarle | Nov 25, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Gender, Other Health Impairment, Sex/Sexuality
A recent study published in the Journal of Child Psychology and Psychiatry reveals that females with ADHD are diagnosed approximately four years later than males, potentially leading to a higher burden of concurrent psychiatric conditions and increased utilization of...
by Dan DeMarle | Oct 20, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, Other Health Impairment, Recommended Reading
by Tamara Rosier (2021) “If you have ADHD, your brain doesn’t work in the same way as a “normal” or neurotypical brain does because it’s wired differently. You and others may see this difference in circuitry as somehow wrong or...
by Dan DeMarle | Oct 16, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Other Health Impairment
“Attention Deficit/Hyperactivity Disorder (ADHD) is one of the most prevalent neurodevelopmental disorders and can persist into adulthood in the majority of cases. ADHD is associated with deficits in cognitive functions, in particular executive functions such as...
by Dan DeMarle | Oct 12, 2024 | ADHD, Attention Deficit Hyperactivity Disorder, Medicine, Other Health Impairment
“The U.S. Food and Drug Administration has approved Tris Pharma’s once-daily Onyda XR (clonidine hydrochloride) as the first liquid, nonstimulant treatment for attention-deficit/hyperactivity disorder (ADHD). The once-a-day, extended-release, oral...
